And then we have another one in Boulder, which is PTSD from any source using...we always use a male/female therapist team, so that the patient can relate to either a man or a woman. That study, we're doing one experienced therapist paired with an intern, so we can see if that works just as well. And then we have smaller studies in Israel, where they have have a lot of war trauma that they're trying to cure and heal, and then a study in Vancouver.
All of these will done this year. We will take this phase two data, and we will summarize it and take it to the FDA, and then get permission, we believe, that will be approved. So we will go to phase three and then work with hundreds of subjects. That we hope to be have done by 2021, when we will have MDMA as a prescription. Well, actually, MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder. That is also something unusual, and it's unusual in this therapy going forward.
I think with psychedelics, there's a general sense among the therapists that you don't do this without a therapist, or a shaman in the case of an ayahuasca or an ibogaine experience, because they're such powerful drugs. And there's a body of research that supports its safe and beneficial use, so you might as well use that experience in the works that we're doing and others are doing with it now. So we hope to have this as a prescription drug for post-traumatic stress disorder. We also have two smaller studies, one for MDMA-assisted psychotherapy for people on the autism spectrum, adults on the autism spectrum, and that is also showing...we just published a paper on that. It's showing also very positive results.
Because we're trying to address the anxiety, and it seems like the MDMA-assisted psychotherapy addresses trauma, anxiety, depression, these kinds of things. We have another parallel track with MDMA-assisted psychotherapy for the fear of death for people with life threatening illnesses, and that's happening in Murin [SP]. That started last week, so it's just begun. We also have four parallel studies using MDMA with people who are in the Veterans Administration in the Department of Defense. We're working in partnership with them. So will MDMA help current therapies?
And so we have four small studies that are not really part of the phase two drug development plan, but there's parallel studies to help us understand more about post-traumatic stress disorder, and to help people working on post-traumatic stress disorder understand more about MDMA and psychedelic psychotherapy. So there's a real nice relationship beginning there. It started small, but we've done a little bit great about helping with relationships with those people.
All of these will done this year. We will take this phase two data, and we will summarize it and take it to the FDA, and then get permission, we believe, that will be approved. So we will go to phase three and then work with hundreds of subjects. That we hope to be have done by 2021, when we will have MDMA as a prescription. Well, actually, MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder. That is also something unusual, and it's unusual in this therapy going forward.
I think with psychedelics, there's a general sense among the therapists that you don't do this without a therapist, or a shaman in the case of an ayahuasca or an ibogaine experience, because they're such powerful drugs. And there's a body of research that supports its safe and beneficial use, so you might as well use that experience in the works that we're doing and others are doing with it now. So we hope to have this as a prescription drug for post-traumatic stress disorder. We also have two smaller studies, one for MDMA-assisted psychotherapy for people on the autism spectrum, adults on the autism spectrum, and that is also showing...we just published a paper on that. It's showing also very positive results.
Because we're trying to address the anxiety, and it seems like the MDMA-assisted psychotherapy addresses trauma, anxiety, depression, these kinds of things. We have another parallel track with MDMA-assisted psychotherapy for the fear of death for people with life threatening illnesses, and that's happening in Murin [SP]. That started last week, so it's just begun. We also have four parallel studies using MDMA with people who are in the Veterans Administration in the Department of Defense. We're working in partnership with them. So will MDMA help current therapies?
And so we have four small studies that are not really part of the phase two drug development plan, but there's parallel studies to help us understand more about post-traumatic stress disorder, and to help people working on post-traumatic stress disorder understand more about MDMA and psychedelic psychotherapy. So there's a real nice relationship beginning there. It started small, but we've done a little bit great about helping with relationships with those people.
